Phio Pharmaceuticals Corp (PHIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -5,173 | -2,642 | -13,287 | -9,836 | -6,094 |
| Depreciation Amortization | 41 | 22 | 75 | 55 | 36 |
| Accounts payable and accrued liabilities | 865 | 46 | -445 | -406 | -380 |
| Other Working Capital | -1,095 | -1,065 | 990 | 198 | -487 |
| Other Operating Activity | -536 | 170 | 809 | 602 | 404 |
| Operating Cash Flow | $-5,898 | $-3,469 | $-11,858 | $-9,387 | $-6,521 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -114 | -104 | -51 | -51 | -21 |
| Investing Cash Flow | $-114 | $-104 | $-51 | $-51 | $-21 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | N/A | 21,723 | 21,723 | 21,723 |
| Other Financing Activity | -25 | -25 | -1 | 0 | 0 |
| Financing Cash Flow | $-25 | $-25 | $21,722 | $21,723 | $21,723 |
| Beginning Cash Position | 24,107 | 24,107 | 14,294 | 14,294 | 14,294 |
| End Cash Position | 18,070 | 20,509 | 24,107 | 26,579 | 29,475 |
| Net Cash Flow | $-6,037 | $-3,598 | $9,813 | $12,285 | $15,181 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,898 | -3,469 | -11,858 | -9,387 | -6,521 |
| Capital Expenditure | -114 | -104 | -51 | -51 | -21 |
| Free Cash Flow | -6,012 | -3,573 | -11,909 | -9,438 | -6,542 |